Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Liberty Global Ltd Class C (LBTYK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Liberty Global Ltd Class C — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.78 (market cap $4.49B), while Liberty Global Ltd Class C trades at $10.4 (market cap $3.60B). The key difference: ACADIA Pharmaceuticals Inc. is the larger of the two by market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Liberty Global Ltd Class C nearer its low. Which is the better fit depends on your goals.
| ACAD | LBTYK | |
|---|---|---|
Market Cap | $4.49B | $3.60B |
Sector | Health | Technology |
52-Week High | $28.06 | $12.67 |
52-Week Low | $20.06 | $10.07 |
Enterprise Value | $3.69B | $10.89B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
LBTYK trades at $10.50, down 3.67% today, with a bearish technical signal and mixed fundamentals. The company reported a net loss of $7.14B in 2025 despite $4.88B revenue, though recent Q1 2026 earnings beat expectations. Analyst sentiment remains positive with 69% buy ratings, while technical indicators show resistance at $11 and support at $10.
The outlook hinges on the planned 2027 Ziggo Group spin-off, which could unlock value, but persistent losses and high debt-to-asset ratio of 38.39% pose significant risks. Near-term catalysts include Q2 2026 results in July, with the stock offering speculative upside if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Liberty Global Ltd Class C
Liberty Global is a world leader in converged broadband, video, and mobile communications. It operates large-scale fiber and 5G networks across Europe, providing essential digital services to millions of customers.
Read more on LBTYK →
